VRNS Varonis Systems RESULTS: Q2, Q2 Operating Income $-40.631M, Q2 REV $180.023M vs. EST $176.8M, Q2 Net Income $-46.809M, Q2 gross profit
VRNS Varonis Systems RESULTS: Q2, Q2 Operating Income $-40.631M, Q2 REV $180.023M vs. EST $176.8M, Q2 Net Income $-46.809M, Q2 gross profit $135.511M
Story updates
08:13:47 PM UTC
SquawkNews
NEO Neogenomics RESULTS: Q2, Q2 REV $202M vs. EST $197M, Q2 ADJ EBITDA $14M, Q2 ADJ Net Income $7M, Q2 gross profit $92M, Q2 operating expenses $102M, Q2 Net Income $2M, Q2 EPS $0.02, Q2 ADJ EPS $0.05 vs. EST $0.03, Neogenomics Earnings Notes:, Outlook FY REV $802-806M, Sees FY2026 ADJ EBITDA $56M to $58M\n, Expects FY2026 net loss of $42M to $34M\n, Decrease in operating expenses for Q2 2026 was primarily due to $20M of impairment charges taken in Q2 2025
NEO Neogenomics RESULTS: Q2, Q2 REV $202M vs.
EST $197M, Q2 ADJ EBITDA $14M, Q2 ADJ Net Income $7M, Q2 gross profit $92M, Q2 operating expenses $102M, Q2 Net Income $2M, Q2 EPS $0.02, Q2 ADJ EPS $0.05 vs.
EST $0.03, Neogenomics Earnings Notes:, Outlook FY REV $802-806M, Sees FY2026 ADJ EBITDA $56M to $58M\n, Expects FY2026 net loss of $42M to $34M\n, Decrease in operating expenses for Q2 2026 was primarily due to $20M of impairment charges taken in Q2 2025